[go: up one dir, main page]

MX2009002999A - Analogos de insulina resistentes a proteasa. - Google Patents

Analogos de insulina resistentes a proteasa.

Info

Publication number
MX2009002999A
MX2009002999A MX2009002999A MX2009002999A MX2009002999A MX 2009002999 A MX2009002999 A MX 2009002999A MX 2009002999 A MX2009002999 A MX 2009002999A MX 2009002999 A MX2009002999 A MX 2009002999A MX 2009002999 A MX2009002999 A MX 2009002999A
Authority
MX
Mexico
Prior art keywords
insulin analogues
insulin
protease resistant
analogues
resistant insulin
Prior art date
Application number
MX2009002999A
Other languages
English (en)
Inventor
Svend Havelund
Per Balschmidt
Svend Ludvigsen
Ulla Ribel-Madsen
Frantisek Hubalek
Peter Kresten Nielsen
Inger Lautrup-Larsen
Per Noergaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38754488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009002999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2009002999A publication Critical patent/MX2009002999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con análogos de insulina novedosos que exhiben resistencia hacia la proteasa, en donde al menos dos aminoácidos están sustituidos y/o suprimidos con relación a la molécula de insulina progenitora. También se proporciona un método para el tratamiento de estos análogos de insulina, las preparaciones de insulina que contienen los análogos de insulina de la invención y un método de tratamiento de diabetes mellitus usando estos análogos de insulina.
MX2009002999A 2006-09-22 2007-09-20 Analogos de insulina resistentes a proteasa. MX2009002999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121113 2006-09-22
PCT/EP2007/059990 WO2008034881A1 (en) 2006-09-22 2007-09-20 Protease resistant insulin analogues

Publications (1)

Publication Number Publication Date
MX2009002999A true MX2009002999A (es) 2009-04-01

Family

ID=38754488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002999A MX2009002999A (es) 2006-09-22 2007-09-20 Analogos de insulina resistentes a proteasa.

Country Status (20)

Country Link
US (1) US9018161B2 (es)
EP (2) EP2074141B1 (es)
JP (2) JP5864834B2 (es)
KR (2) KR101699370B1 (es)
CN (1) CN101541830A (es)
AU (1) AU2007298919C1 (es)
BR (1) BRPI0717098B8 (es)
CA (1) CA2663074A1 (es)
DK (1) DK2074141T3 (es)
ES (1) ES2601839T3 (es)
HU (1) HUE029512T2 (es)
IL (1) IL197609A (es)
MX (1) MX2009002999A (es)
NO (1) NO20091563L (es)
PL (1) PL2074141T3 (es)
PT (1) PT2074141T (es)
RU (1) RU2524150C2 (es)
TW (1) TW200829600A (es)
WO (1) WO2008034881A1 (es)
ZA (1) ZA200901838B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
WO2008132224A2 (en) 2007-04-30 2008-11-06 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2164459A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK2229407T3 (en) 2008-01-09 2017-02-27 Sanofi Aventis Deutschland NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE
EP2254905B1 (en) * 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
PT2254906T (pt) 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
WO2009133099A2 (en) * 2008-04-28 2009-11-05 Novo Nordisk A/S Insulin precursors for diabetes treatment
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
CN102245633A (zh) * 2008-12-09 2011-11-16 诺沃—诺迪斯克有限公司 新的胰岛素类似物
RU2533217C3 (ru) 2009-06-26 2020-12-21 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
TW201113032A (en) * 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
WO2011033019A1 (en) 2009-09-16 2011-03-24 Novo Nordisk A/S Stable non-aqueous liquid pharmaceutical compositions comprising an insulin
EP2496213B1 (en) 2009-11-02 2015-08-12 Novo Nordisk A/S Pharmaceutical solution of non covalently bound albumin and acylated insulin
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
EP2523655A2 (en) 2010-01-12 2012-11-21 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8815798B2 (en) 2010-06-23 2014-08-26 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
BR112012033107A2 (pt) 2010-06-23 2016-10-11 Novo Nordisk As derivados de insulina contendo ligações dissulfeto adicionais.
US8883722B2 (en) 2010-06-23 2014-11-11 Novo Nordisk A/S Human insulin containing additional disulfide bonds
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
EP2627670A2 (en) 2010-10-15 2013-08-21 Novo Nordisk A/S Novel n-terminally modified insulin derivatives
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
EP2651446A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
US20130331320A1 (en) 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
EP2696847A1 (en) 2011-04-14 2014-02-19 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
ES2550357T3 (es) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059213A1 (en) * 2011-10-18 2013-04-25 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
WO2014060447A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated d-amino acids for oral peptide delivery
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2014161952A1 (en) 2013-04-05 2014-10-09 Novo Nordisk A/S Dose logging device for a drug delivery device
US9163073B2 (en) 2013-04-17 2015-10-20 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR102578030B1 (ko) 2014-12-12 2023-09-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 글라진／릭시세나티드 고정비 제형
WO2016119854A1 (en) * 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP3487876A4 (en) 2016-07-22 2020-02-19 University of Utah Research Foundation INSULIN ANALOGS
KR102698929B1 (ko) * 2016-09-23 2024-08-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
EP3529615A1 (en) * 2016-10-24 2019-08-28 Novo Nordisk A/S Bioassay for insulin formulations
EP3534962B1 (en) 2016-11-07 2020-08-19 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
MX389336B (es) 2016-11-15 2025-03-20 Klaria Pharma Holding Ab Formulacion farmaceutica.
TWI700091B (zh) 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
AR111341A1 (es) * 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
US11471537B2 (en) 2017-04-05 2022-10-18 Novo Nordisk A/S Oligomer extended insulin-Fc conjugates
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
JP2020531451A (ja) 2017-08-17 2020-11-05 ノヴォ ノルディスク アー／エス 新規のアシル化インスリン類似体およびそれらの使用
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR102646845B1 (ko) 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
US11541122B2 (en) 2018-09-19 2023-01-03 Ziylo Limited Glucose sensitive insulins and uses thereof
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
WO2020120479A1 (en) 2018-12-11 2020-06-18 Sanofi Peptide binder
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
CN114867743A (zh) 2019-12-10 2022-08-05 赛诺菲 形成磺酰胺与多肽的缀合物的方法
AU2021273262A1 (en) 2020-05-15 2022-12-08 Eli Lilly And Company Extended time action acylated insulin compounds
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof
CN116284433B (zh) * 2022-07-04 2023-09-12 北京惠之衡生物科技有限公司 一种胰岛素和glp-1的缀合物及其应用
WO2024194897A1 (en) * 2023-03-22 2024-09-26 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) A glycation resistant insulin polypeptide and a method of preparing the same thereof

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832685A (en) * 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) * 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
FI910286A0 (fi) * 1988-07-20 1991-01-18 Nordisk Gentofte Analoger av humant insulin och preparat innehaollande dessa.
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5716927A (en) * 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
EP0469084B1 (en) 1989-04-20 1995-04-05 Mount Sinai School Of Medicine Of The City University Of New York Hepatospecific insulin analogues
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2027930C (en) * 1989-10-19 1998-06-30 Tsuyoshi Miyazaki Polymer complexes of a sugar response type
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
DK45590D0 (es) 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK158390D0 (da) * 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
AU8091091A (en) 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
CA2268476A1 (en) * 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
TW224471B (es) 1991-11-26 1994-06-01 Lilly Co Eli
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
KR100310122B1 (ko) 1993-09-17 2002-04-24 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 아실화된인슐린
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
GB9323588D0 (en) 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
EP2036541A1 (en) 1994-03-07 2009-03-18 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
KR19980703039A (ko) 1995-03-17 1998-09-05 켈스버그 라아스 인슐린 유도체
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
WO1996034882A1 (en) 1995-05-05 1996-11-07 Eli Lilly And Company Single chain insulin with high bioactivity
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US20030104981A1 (en) * 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
WO1998001473A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
ES2230607T3 (es) 1996-07-11 2005-05-01 Novo Nordisk A/S Metodo selectivo de acilacion.
DK0821006T3 (da) * 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
EP0954589A1 (en) 1997-01-24 1999-11-10 Novo Nordisk A/S Synthetic leader peptide sequences
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
PE123799A1 (es) 1997-10-24 1999-12-13 Lilly Co Eli Composiciones insolubles de insulina
ES2202899T3 (es) 1997-10-24 2004-04-01 Novo Nordisk A/S Agregados de derivados de la insulina humana.
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
AU1375199A (en) 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
CA2334859A1 (en) 1998-06-12 1999-12-23 Kings College London Insulin analogue
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
DE69936386T2 (de) 1998-08-25 2008-03-06 Advanced Inhalation Research, Inc., Cambridge Sprühgetrocknete proteinformulierungen
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
HUP0104111A3 (en) 1998-10-16 2002-05-28 Novo Nordisk As Stable concentrated insulin preparations for pulmonary delivery
US6660715B2 (en) * 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
ES2180511T3 (es) 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
WO2000064940A1 (en) 1999-04-27 2000-11-02 Eli Lilly And Company Insulin crystals for pulmonary administration
US6746853B1 (en) * 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
AU5144400A (en) 1999-05-19 2000-12-05 Xencor, Inc. Novel proteins with insulin-like activity useful in the treatment of diabetes
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
CN1160122C (zh) * 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
MY137181A (en) 2001-05-21 2009-01-30 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7186797B2 (en) * 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
MY127575A (en) 2001-09-07 2006-12-29 Biocon Ltd Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
WO2003047493A2 (en) 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
EP1456371A1 (en) * 2001-12-05 2004-09-15 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE60335797D1 (de) 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN1165549C (zh) 2002-06-15 2004-09-08 江苏万邦生化医药股份有限公司 胰岛素的纯化方法
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
PL1648933T3 (pl) 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Długo działające pochodne insuliny i związane z tym sposoby
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
DK1660047T3 (en) 2003-08-13 2014-03-10 Biocon Ltd MICROPARTICALLY FATIC ACID SALT SOLID DOSAGE FORMS FOR THERAPEUTIC AGENTS
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
DE10358387A1 (de) 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
WO2006060753A2 (en) * 2004-12-03 2006-06-08 Rhode Island Hospital Diagnosis and treatment of alzheimer's disease
WO2006079641A2 (en) 2005-01-27 2006-08-03 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
WO2006082205A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1846446B1 (en) * 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
WO2007006320A1 (en) 2005-07-12 2007-01-18 Sherine Hassan Abbas Helmy Drinkable oral insulin liquid and capsules
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
US20100210506A1 (en) 2005-10-20 2010-08-19 Mdrna, Inc. Intranasal administration of rapid acting insulin
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007096332A1 (en) 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
EP1996223A1 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
BRPI0717098B8 (pt) * 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
US20100120660A1 (en) 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
WO2008145728A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2164459A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
CN101743252A (zh) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
EP2017288A1 (en) 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CN101784562B (zh) 2007-08-15 2016-07-13 诺沃-诺迪斯克有限公司 具有酰基和亚烷基二醇部分的胰岛素类似物
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
PT2254906T (pt) * 2008-03-18 2017-01-03 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases

Also Published As

Publication number Publication date
AU2007298919A1 (en) 2008-03-27
PT2074141T (pt) 2016-11-10
RU2524150C2 (ru) 2014-07-27
JP2010504087A (ja) 2010-02-12
IL197609A (en) 2017-04-30
ES2601839T3 (es) 2017-02-16
AU2007298919C1 (en) 2014-02-06
PL2074141T3 (pl) 2017-02-28
NO20091563L (no) 2009-04-20
WO2008034881A1 (en) 2008-03-27
US9018161B2 (en) 2015-04-28
EP2404934A1 (en) 2012-01-11
JP5864834B2 (ja) 2016-02-17
HUE029512T2 (en) 2017-03-28
BRPI0717098A2 (pt) 2013-10-08
US20100009898A1 (en) 2010-01-14
EP2074141B1 (en) 2016-08-10
RU2009114324A (ru) 2010-10-27
TW200829600A (en) 2008-07-16
KR20150031494A (ko) 2015-03-24
DK2074141T3 (en) 2016-11-28
EP2074141A1 (en) 2009-07-01
BRPI0717098B8 (pt) 2021-05-25
BRPI0717098B1 (pt) 2018-08-07
CA2663074A1 (en) 2008-03-27
KR20090071561A (ko) 2009-07-01
JP2014129355A (ja) 2014-07-10
KR101699370B1 (ko) 2017-02-14
KR101729986B1 (ko) 2017-04-25
ZA200901838B (en) 2010-02-24
IL197609A0 (en) 2011-08-01
CN101541830A (zh) 2009-09-23

Similar Documents

Publication Publication Date Title
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
MXPA06001283A (es) Derivados de insulina novedosos.
WO2008106130A3 (en) Tertiary amine substituted peptides useful as inhibitors of hcv replication
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
DE60110054D1 (en) Cardioprotektive phosphonate
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
MX2009006199A (es) Formulacion parenteral de anticuerpos abeta.
WO2008012629A3 (en) Exendin fusion proteins
EP2070946A3 (de) Erfindung betreffend GLP-1 und Exendin
WO2005082928A3 (en) Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity
EP2202310A3 (en) Caustic stable chromatography ligands
WO2008081701A1 (ja) Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
CY1109269T1 (el) Συνθεσεις πρωτεϊνων συντηξεως αναλογων glp-1
WO2005115306A3 (de) Keratin-bindende polypeptide
WO2006094974A3 (en) Chemically defined stabiliser composition
WO2007104738A3 (en) Acylated single chain insulin
MX2009006617A (es) Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
WO2008155900A1 (ja) 糖鎖付加glp-1ペプチド
MY149128A (en) A method for the mass production of immunoglobulin fc region deleted initial methionine residues
ATE517917T1 (de) Herstellung eines rekombinanten il-18-bindenden proteins
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
PT1951747E (pt) Processo e intermediários para a síntese de caspofungina
NZ596501A (en) Casb7439 constructs
DK1066328T3 (da) Kimært protein, der indeholder en intramolekylær chaperon-lignende sekvens, og dets anvendelse til insulinproduktion

Legal Events

Date Code Title Description
FG Grant or registration